BACKGROUND AND AIMS:
Utilization and security of cannabidiol (CBD) in sufferers with autoimmune hepatitis (AIH) are at the moment unknown. We aimed to recognize the frequency of CBD use, influence on symptoms, and security profile.
An invitation to comprehensive a CBD-distinct questionnaire was posted each and every other day to nicely-established autoimmune hepatitis Facebook communities (combined membership of 2600 men and women) through a 10-day study period. Age ≥ 18 years and an AIH diagnosis by a doctor have been the eligibility criteria for participation in the survey.
In total, 371 AIH sufferers (median age 49 years, 32% reported sophisticated fibrosis) completed the questionnaire. Respondents have been 91% girls, 89% Caucasian, and 89% from North America. Ninety-3 (25%) respondents have been ever CBD customers, with 55 of them (15% of the survey responders) identified as existing customers. Amongst ever customers, 45.7% reported their treating physicians have been conscious of their CBD use. The most popular cause cited for CBD use was discomfort (68%), poor sleep (62%), and fatigue (38%). Most respondents applying CBD for these symptoms reported a substantial improvement in discomfort (82%), sleep (87%), and fatigue (61%). In ever CBD customers, 17.three% have been in a position to quit a prescription medication since of CBD use: discomfort medication (47%), immunosuppression (24%), and sleep aids (12%). Side effects attributed to CBD use have been reported in three% of CBD customers, however there have been no reported emergency division visits or hospitalizations.
CBD use was not uncommon in sufferers with AIH, and its use was linked with reports of improvement in extrahepatic symptoms.